181 related articles for article (PubMed ID: 36579993)
1. Minilaparotomy, Cyfra21-1, and Other Predicting Factors for Suboptimal Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer: A Pilot Study.
Nantasupha C; Pojchamarnwiputh S; Charoenkwan K
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4119-4124. PubMed ID: 36579993
[TBL] [Abstract][Full Text] [Related]
2. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
Feng LY; Liao SB; Li L
J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
[TBL] [Abstract][Full Text] [Related]
3. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
4. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
[TBL] [Abstract][Full Text] [Related]
5. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma.
Tang Z; Chang X; Ye X; Li Y; Cheng H; Cui H
Chin J Cancer Res; 2015 Jun; 27(3):309-17. PubMed ID: 26157328
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer.
Paunovic V; Protrka Z; Ardalic D; Paunovic T
J BUON; 2017; 22(1):29-33. PubMed ID: 28365932
[TBL] [Abstract][Full Text] [Related]
8. To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy.
Kumari A; Thakur M; Saha SC; Suri V; Prasad GRV; Patel FD; Radhika S
J Obstet Gynaecol; 2021 May; 41(4):616-620. PubMed ID: 32811236
[TBL] [Abstract][Full Text] [Related]
9. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
10. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
[TBL] [Abstract][Full Text] [Related]
12. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
13. The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer.
Turnbull HL; Akrivos N; Wemyss-Holden S; Maiya B; Duncan TJ; Nieto JJ; Burbos N
Arch Gynecol Obstet; 2017 Mar; 295(3):681-687. PubMed ID: 27995370
[TBL] [Abstract][Full Text] [Related]
14. Preoperative serum level of CA153 and a new model to predict the sub-optimal primary debulking surgery in patients with advanced epithelial ovarian cancer.
Jia Y; Jiang Y; Fan X; Zhang Y; Li K; Wang H; Ning X; Yang X
World J Surg Oncol; 2024 Feb; 22(1):64. PubMed ID: 38395933
[TBL] [Abstract][Full Text] [Related]
15. Association between the quantitative characteristics of dual-energy spectral CT and cytoreduction surgery outcome in patients with advanced epithelial ovarian cancers: A prospective observational study.
Xu X; Chen Y; Zhang X; Wang Y
Medicine (Baltimore); 2024 Mar; 103(10):e37437. PubMed ID: 38457565
[TBL] [Abstract][Full Text] [Related]
16. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.
Memarzadeh S; Lee SB; Berek JS; Farias-Eisner R
Int J Gynecol Cancer; 2003; 13(2):120-4. PubMed ID: 12657110
[TBL] [Abstract][Full Text] [Related]
17. Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer.
Arab M; Jamdar F; Sadat Hosseini M; Ghodssi- Ghasemabadi R; Farzaneh F; Ashrafganjoei T
Asian Pac J Cancer Prev; 2018 May; 19(5):1319-1324. PubMed ID: 29802693
[TBL] [Abstract][Full Text] [Related]
18. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?
Angioli R; Plotti F; Capriglione S; Aloisi A; Montera R; Luvero D; Miranda A; Cafà EV; Damiani P; Benedetti-Panici P
Gynecol Oncol; 2013 Mar; 128(3):579-83. PubMed ID: 23220563
[TBL] [Abstract][Full Text] [Related]
19. Validation of the Integrated Prediction Model algorithm for outcome of cytoreduction in advanced ovarian cancer.
Piedimonte S; Bernardini MQ; Ding A; Laframboise S; Ferguson SE; Bouchard-Fortier G; Avery L; May T; Hogen L
Int J Gynecol Cancer; 2023 Jul; 33(7):1077-1082. PubMed ID: 37015756
[TBL] [Abstract][Full Text] [Related]
20. Oncologic outcomes in patients undergoing maximal or optimal cytoreductive surgery for Stage 3C serous ovarian, tubal or peritoneal carcinomas.
Gurkan D; Ceren Akin A; Sahin H; Aytac Tohma Y; Sahin EA; Gunakan E; Iflazoglu N; Nihan Haberal A; Ayhan A
J Obstet Gynaecol; 2020 May; 40(4):551-557. PubMed ID: 31482736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]